What PolyPeptide Group does

PolyPeptide Group operates a direct-to-consumer e-commerce storefront (polypeptide.group) selling research-grade peptides globally. Founded in 2014, the company markets a catalog of approximately fifteen peptide products, with Somatropin (recombinant human growth hormone, 191 amino acids) as its core offering, supplemented by a range of research peptides spanning growth hormone secretagogues (CJC-1295, Ipamorelin, GHRP-2, GHRP-6), IGF-1 variants (IGF1-LR3, PEG-MGF), recovery and pigmentation peptides (TB-500, Melanotan 2, Frag 176-191, Follistatin), and gonadotropins (HCG, Gonadorelin). All SKUs are labeled "for research use only," yet the website's marketing language is overtly consumer-oriented, emphasizing anti-aging, cellular regeneration, fat metabolism, and hormone-replacement use cases for individual buyers. Shipments include authenticity features (original cartons, holograms, serial codes) intended to deter counterfeit competition.

The underlying technology is described as peptide bioregulation — identification and isolation of biologically active short peptides — supported by an asserted "colossal scientific and laboratory base," though no specific scientific personnel, patents, certifications, or manufacturing facilities are disclosed. The business model is a straightforward one-time-purchase DTC storefront with no disclosed pricing, no subscription tiers, and no enterprise or B2B contracts documented; the only public contact channel is a single email address and contact form with weekday business hours. A May 2023 strategic partnership with Numaferm GmbH focused on sustainable peptide manufacturing is the most significant third-party relationship on record, but no downstream operational impact (capacity, supply, co-developed products) is documented in the source data.

Key structural caveats: the firmographics short description characterizes the company as a CDMO for pharma and biotech — this is inconsistent with the actual website, which is a small consumer storefront, and is treated as unreliable for purposes of this analysis. No revenue, funding, headcount specifics, management team, regulatory clearances, or financial statements are disclosed. The product category (research-use peptides marketed with consumer health claims) operates in a gray regulatory zone that materially affects the risk profile.

Name

PolyPeptide Group

Legal name

Polypeptide group

Website

https://polypeptide.group

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

251–500 employees

Short description

PolyPeptide Group is a 2014-founded direct-to-consumer e-commerce seller of research-grade peptides, with Somatropin as its core product and ~15 ancillary peptide SKUs, marketing anti-aging and cellular-regeneration benefits to individual global buyers via its own website.

Ownership category

akta.pro rank

Product category

Pharmaceutical peptides

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine) (AFAJAKAG), Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids) (CRADAOAJ)

Keywords

• Peptide manufacturing
• Recombinant growth hormone
• Research peptides
• Pharmaceutical peptides
• Peptide bioregulation

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Peptide Product Sales: Direct sales of peptide products including Somatropin, TB-500, PEG-MGF, Melanotan 2, Ipamorelin, IGF1-LR3, HCG, Gonadorelin, GHRP-6, GHRP-2, Frag(176-191), Follistatin, and CJC-1295. Products are shipped directly to customers with authenticity verification.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

PolyPeptide Group develops and sells peptide products directly to end customers through its e-commerce website. The portfolio centers on recombinant human growth hormone (Somatropin 191aa) and a catalog of research peptides covering growth hormone secretagogues, IGF variants, melanocortin peptides, tissue-recovery peptides, and gonadotropins. Products ship in original cartons with protective holograms and serial codes for authenticity verification.

Product overview

PolyPeptide Group is a pharmaceutical peptide products company established in 2014, specializing in recombinant human growth hormone (Somatropin 191aa) and research peptides for biological research. The company's product portfolio centers on Somatropin as the core pharmaceutical product for treating growth hormone deficiency, supported by a range of research peptides including growth hormone-releasing peptides (GHRP-2, GHRP-6, CJC-1295, Ipamorelin), IGF-related peptides (IGF1-LR3, PEG-MGF, Follistatin), pigmenting peptides (Melanotan 2), and tissue-recovery peptides (TB-500, Frag 176-191), along with gonadotropins (HCG, Gonadorelin). All peptide products are labeled for laboratory research purposes only.

Differentiator

Problem solved

Functional benefit

Products and services

• Somatropin 191aa Recombinant human growth hormone (rDNA origin injection) of 191 amino acids identical to natural pituitary growth hormone, used to treat growth failure in children and growth hormone deficiency in adults, including cases of Noonan Syndrome, Turner Syndrome, and short stature born small for gestational age.
• CJC-1295 30-amino-acid peptide hormone analogue of somatoliberin that stimulates growth hormone secretion and can bioconjugate with serum albumin to extend half-life and therapeutic effect.
• GHRP-6 Hexapeptide growth hormone secretagogue that stimulates ghrelin receptors and promotes endogenous growth hormone production.
• GHRP-2 Growth hormone-releasing peptide that stimulates independent growth hormone production through pituitary and hypothalamic receptor interaction.
• Ipamorelin Growth hormone stimulating peptide from the GHRP group that mimics ghrelin effects and enhances growth hormone secretion with minimized side effects.
• IGF1-LR3 Insulin-like growth factor-1 variant with extended half-life that provides anabolic effects including increased muscle mass through hyperplasia.
• PEG-MGF Pegylated mechanical growth factor, an isoform of insulin-like growth factor formed after physical exercise that promotes muscle cell division and growth.
• Follistatin 344 Protein with high affinity for binding to activin and myostatin, functioning as an inhibitor of these proteins to promote muscle growth.
• Melanotan 2 Analogue of melanocyte stimulating hormone (alpha-MSH) that activates melanin production for skin tanning and provides UV protection.
• TB-500 Synthetic analogue of natural thymosin beta-4, a peptide hormone involved in healing, recovery from trauma, and immunity strengthening.
• HGH Frag (176-191) 16-amino-acid fragment of growth hormone that stimulates lipolysis and suppresses subcutaneous fat formation without affecting blood sugar levels.
• HCG 2000 IU Human chorionic gonadotropin (2000 IU lyophilizate) that mimics luteinizing hormone action for use in fertility treatments and testosterone stimulation.
• Gonadorelin Gonadotropin-releasing hormone (GnRH) polypeptide that stimulates pituitary gonadotropin release and supports testosterone production and spermatogenesis.

Quantifiable outcome

• Peptides are cleaved to amino acids and used as building material by the body after performing their function
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Numaferm GmbHcoreStrategic or Co-development Partner · 1 May 2023Partnership established in May 2023 between PolyPeptide Group AG and Numaferm GmbH focused on sustainable peptide manufacturing innovations. This collaboration highlights strategic industry partnerships driving sustainable development in the peptide manufacturing sector.

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Limitless Life Nootropics: Online retailer of novel compounds including research peptides, nootropics, and longevity supplements; competes for the same DTC wellness/bioregulation buyer seeking growth-hormone-axis products.
• Peptide Sciences: Online research-peptide retailer offering Somatropin, GHRP-6, Melanotan II, and other recombinant and synthetic peptides targeted at the same research/longevity buyer as PolyPeptide Group. Closest comparable in catalog, pricing, and DTC delivery model.
• Amino Asylum (Peptide Source): Specialty online retailer of research-use-only peptides including growth hormone secretagogues, melanocortins, and recovery peptides — directly comparable catalog and customer base to PolyPeptide Group's research-peptide line.
• Bioactive Peptides (research peptide vendors — category): Independent research-peptide vendors selling GHRPs, CJC-1295, IGF-1 variants, and HCG online with similar 'research only' positioning. Represents the direct peer set PolyPeptide Group competes with for share of wallet.

Broad incumbents

• Novo Nordisk: Global leader in therapeutic growth hormone (Norditropin, Sogroya) with established regulatory, manufacturing, and physician-channel infrastructure. Represents the legitimate, branded incumbent whose prescription HGH business PolyPeptide's Somatropin indirectly competes against.
• Bachem Holding AG: Leading peptide and oligonucleotide CDMO serving pharmaceutical customers worldwide with GMP-grade manufacturing. Comparable because PolyPeptide's 'colossal scientific and laboratory base' claims map to Bachem's manufacturing platform expertise at industrial scale.
• Pfizer (Genotropin): Sells the Genotropin brand of recombinant somatropin through physician and specialty pharmacy channels. Comparable as a manufacturer and distributor of the recombinant human growth hormone at the center of PolyPeptide Group's core product.
• Eli Lilly (Humatrope / eglume): Major diversified pharmaceutical company with a long-established Humatrope recombinant growth hormone franchise serving the same adult and pediatric growth-hormone-deficiency indications that PolyPeptide's Somatropin targets.

Emerging players

• PolyPeptide Group AG (the legitimate Swiss-listed CDMO): Publicly-listed, EU-based peptide and oligonucleotide CDMO manufacturing APIs for pharma and biotech. Relevant emerging/thematic peer because the supplied PolyPeptide Group short description references the same CDMO business model — brand-name overlap demands diligence to ensure the two are distinct.

Others

• Defy Medical / telemedicine HRT clinics: Telemedicine and clinic channels dispensing growth hormone, peptides, and hormone-optimization therapies to consumers. Comparable as a downstream customer/distribution channel that PolyPeptide's research-positioned products could increasingly feed.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PolyPeptide Group